trending Market Intelligence /marketintelligence/en/news-insights/trending/IqB7HD2R6sDEE83Y0__oIg2 content esgSubNav
In This List

Pharma moves through Oct. 4

Video

S&P Capital IQ Pro | Unrivaled Sector Coverage

Video

S&P Capital IQ Pro | Powering Your Edge

Blog

Enterprises are missing out on 24B by not optimizing cloud spending not going multicloud

Blog

Investment Research Analysts Providing Greater Coverage on Inflation


Pharma moves through Oct. 4

S&P Global Market Intelligence presents a weekly rundown of recent executive changes at pharmaceutical, biotech and life sciences companies.

* Eli Lilly and Co. named Josh Smiley to replace Derica Rice as the company's senior vice president and CFO on Jan. 1, 2018.

* Cellectis SA appointed Mathieu Simon as its interim chief medical officer.

* Delivra Corp. appointed Howard Lichtman to the position of chief marketing officer.

* Fredrik Gynnerstedt resigned as the CFO of Oasmia Pharmaceutical AB (publ), to be replaced by Anders Blom on a temporary basis.

* Axovant Sciences Ltd. said Lawrence Friedhoff stepped down as chief development officer but will remain the chief of research and development at Roivant Sciences Ltd., its subsidiary.

* Momenta Pharmaceuticals Inc. promoted Ganesh Kaundinya to the position of COO. Kaundinya is also the chief scientific officer of the company.

* Acerus Pharmaceuticals Corp. said President and CEO Tom Rossi will depart from the company to pursue other opportunities. The company's board appointed Luc Mainville as interim CEO until a new CEO is hired.

* biOasis Technologies Inc. appointed Christopher Lowe as CFO and board adviser.

* CRISPR Therapeutics AG promoted Samarth Kulkarni, president of the company, to the position of CEO. Kulkarni replaces Rodger Novak, co-founder and current CEO, who is stepping down from his current role for personal reasons.

* Emerald Health Therapeutics Inc. appointed Chris Wagner as CEO and board member. Wagner most recently served as chairman, president and CEO of Contextual Genomics Inc.

* Laurel Organics Ltd. named Sanjay Gupta as CFO. Gupta is a chartered accountant with 18 years of experience.

* Halozyme Therapeutics Inc. COO Mark Gergen is leaving the company to pursue professional opportunities elsewhere.

* Kiadis Pharma NV named Andrew Sandler as its chief medical officer. He will succeed Jeroen Rovers, who will assist in the transition until the end of 2017.

* ZIOPHARM Oncology Inc. appointed David Mauney as executive vice president and chief business officer. Mauney joins ZIOPHARM from Harvest Capital Strategies LLC, where he served as a managing director.

* Supreme Pharmaceuticals Inc. named Navdeep Dhaliwal as the company's president. Meanwhile, Dimitre Naoumov was appointed the company's CFO, replacing Dhaliwal.

* Invitrocue Ltd. appointed Ramanuj DasGupta as its nonexecutive chief scientific officer. DasGupta has served as the company's scientific adviser since 2016.